容量限制性结合对血友病A大鼠重组凝血因子VIII与血管性血友病因子药代动力学的影响
本研究在大鼠血友病A模型中建立群体药代动力学模型,描述重组凝血因子VIII(rFVIII)、血管性血友病因子(VWF)及rFVIII:VWF复合物的容量限制性结合动力学。模型采用双室准稳态靶点介导药物处置模型,Kss=0.14 nmol L-1,rFVIII:VWF复合物消除半衰期取决于游离rFVIII血浆浓度;模拟显示高剂量rFVIII治疗可能显著降低内源性VWF水平。
要点
- 双室准稳态靶点介导药物处置模型可描述广泛rFVIII剂量下总rFVIII、总VWF及复合物的药代动力学。
- rFVIII:VWF复合物的消除半衰期取决于游离rFVIII血浆浓度。
- 模拟显示高剂量rFVIII治疗可能显著降低内源性VWF水平。
核心结论
- 在大鼠血友病A模型中建立了群体药代动力学模型,可描述广泛rFVIII剂量下总rFVIII、总VWF及rFVIII:VWF复合物的时间过程。
研究设计与样本
- 基于靶点介导药物处置原理建立群体药代动力学模型,使用血友病A大鼠静脉给予rFVIII(17.5、100、1000、5000 IU kg-1)后的总rFVIII和VWF血浆浓度及rFVIII:VWF复合物发光氧通道免疫分析信号数据。
主要发现
- 双室准稳态靶点介导药物处置模型充分描述了总rFVIII和VWF的血浆浓度-时间曲线及rFVIII:VWF复合物的发光氧通道免疫分析信号-时间曲线(Kss=0.14 nmol L-1)。
- rFVIII:VWF复合物的消除半衰期取决于游离rFVIII血浆浓度。
- 药代动力学模拟显示,高剂量rFVIII治疗可能显著降低内源性VWF水平。
关键数值与推荐
- Kss=0.14 nmol L-1。
- rFVIII给药剂量为17.5、100、1000和5000 IU kg-1。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Knowledge of the interplay between FVIII and VWF pharmacokinetics (PK) is lacking. We characterized the capacity-limited PK of FVIII and VWF. The PK model described the PK of FVIII and VWF over a broad range of rFVIII doses. High-dose rFVIII treatment can reduce the endogenous VWF levels. BACKGROUND: Understanding of the pharmacokinetics (PK) interplay between factor VIII (FVIII) and von Willebrand factor (VWF) following high-dose FVIII treatment is lacking. OBJECTIVES: To characterize the PK of recombinant FVIII (rFVIII), VWF, and the rFVIII:VWF complex in hemophilia A rats following intravenous administration of rFVIII using PK modeling. A second aim was to investigate the effect of high daily dosing and constant expression of rFVIII on VWF exposure using PK simulations. METHODS: We developed a population PK model based on the principles of target-mediated drug disposition modeling, using data on total rFVIII and VWF plasma concentrations, and the rFVIII:VWF complex luminescent oxygen channeling immunoassay signal in hemophilia A rats following intravenous administration of rFVIII (17.5, 100, 1000, and 5000 IU kg-1 ). Additionally, we evaluated the influence of high-dose rFVIII treatment on the exposure of VWF using PK simulations. RESULTS: The plasma concentration-time profiles of total rFVIII and VWF, and the luminescent oxygen channeling immunoassay signal-time profiles of the rFVIII:VWF complex were adequately described using a two-compartment quasi-steady-state target-mediated drug disposition model (Kss = 0.14 nmol L-1 ). The elimination half-life of the rFVIII:VWF complex was dependent on the unbound plasma concentration of rFVIII. Additionally, we showed that high-dose rFVIII treatment may significantly reduce the endogenous VWF levels. CONCLUSIONS: We developed a population-based PK model describing the time-course of total rFVIII, total VWF, and the rFVIII:VWF complex over a broad range of rFVIII doses in hemophilia A rats.
引用
- Vargas Christensen I, Loftager M, Rode F, et al. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats. J Thromb Haemost. 2019. PMID: 30924607. doi:10.1111/jth.14441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。